Lupin Share Price
LUPIN
Lupin Share Price Chart
About Lupin
Lupin Financials
Market cap ₹99,768 Crs | Open ₹2,212.80 | Close ₹2,197.70 |
Circuit range ₹2,417.45 - ₹1,977.95 | Day range ₹2,177.00 - ₹2,218.85 | Year range ₹1,135.00 - ₹2,312.00 |
Volume 11,18,307 | Avg. traded ₹2,192.01 | Revenue (12m) ₹20,797 Crs |
Lupin Limited is an Indian multinational pharmaceutical company. It is one of the largest generic medicine manufacturers globally with its footprint in over 100 countries.
Headquartered in Mumbai, Lupin has a diverse portfolio of more than 1,000 products. The pharma company is among the leaders in business segments like generics, Active Pharmaceutical Ingredients (API), speciality and biologics.
Founded in 1968 by Dr. Desh Bandhu Gupta, a professor of Chemistry, Lupin was incorporated in 1972 and started its business as a vitamin manufacturer. It soon bagged a huge order for supplying iron and folic acid tablets from the central government for the mother and child healthcare programmes.
In 1979, the company commissioned its maiden formulation plant and research and development centre in Aurangabad, Maharashtra. Later, it extended operations beyond India’s borders by establishing Lupin Chemicals (Thailand) through a joint venture in 1989. Around the same time, Lupin obtained United States Food and Drug Agency (USFDA) nod for the Ankleshwar and Mandideep plants.
In their bid to tap the market, Lupin Laboratories Ltd and Lupin Chemicals Ltd floated IPOs successfully in 1993 and were enlisted in the stock exchanges. However, within eight years, both the companies were amalgamated to form the new entity, Lupin Ltd.
In 2003, the company set up Lupin Pharmaceuticals (US) for trading and marketing of drugs in the United States. Within two years the company began its generic medicine business in the country.
2007 was a landmark year for the company, as Lupin announced its maiden issue of $100 million worth Foreign Currency Convertible Bonds (FCCB), and was listed on the Singapore Stock Exchange. Lupin also acquired Japan's Kyowa Pharmaceutical Industry Co, which became its subsidiary.
In the next few years, Lupin acquired or bought partial stakes in several pharmaceutical companies abroad, including South Africa’s Pharma Dynamics, and Generic Health Ltd in Australia.
With its business valuation consistently going up, Lupin found a place in the Nifty 50 index in 2012.
In 2019, Lupin entered into a definitive agreement with Unison - the leading private equity fund in Japan - for the sale of its entire stake in Kyowa Pharmaceutical Industry Co Ltd.
Lupin Limited’s market capitalisation stood at more than ₹62,400 crore as of January 2, 2023. Lupin share price has gone up over 36% in the last three years.
Business operations
Lupin owns and operates 12 manufacturing plants in India at Aurangabad, Ankleshwar, Mandideep, Pune, Tarapur, Goa, Jammu, Vadodara, Indore, Nagpur, Visakhapatnam and Sikkim. It has three manufacturing units abroad in Mexico, Brazil and the US.
It has expanded its business operations across the US, Latin America, Asia Pacific, Europe, the Middle East and Africa. The pharma company is the world’s largest supplier of first-line anti-TB drugs. It’s also the 10th largest generic pharma company globally.
Notwithstanding pricing issues in the US, Lupin recorded $632 million in sales in FY23 there, and continues to be the third-largest pharmaceutical player by prescriptions in the country.
Financial highlights
Total revenue from operations increased by 1.43% to ₹16,641.66 crore in FY23 from ₹16,405.48 crore in FY22. Consolidated EBITDA (earnings before interest, taxes, depreciation,and amortisation) dropped by 18.88% to ₹1,871.5 crore in FY23 from ₹2307.3 crore in FY22. The company reported consolidated profit after tax (PAT) of ₹430 crore in FY23, compared to a loss of ₹1,528 crore in FY22. The company made a total capital expenditure of ₹64,128.8 crore in FY23. The company's earnings per share (EPS) increased to ₹9.46 in FY23 as against ₹(-33.65) recorded in FY22.
Lupin Key indicators
52 week high ₹2,312.00 | 52 week low ₹1,135.00 | P/E ratio 44.18 |
P/B ratio 6.72 | ROE 12% | ROCE 14.33% |
Dividend yield 0.37% | Debt/Equity ratio | EPS 51.04 |
Learn more
Featured in
Equity returns
Dividend returns
Safety factor
Growth factor
Debt vs Equity
Profit factor
The investment checklist helps you understand a company's financial health at a glance and identify quality investment opportunities easily
Analyst ratings:
Analyst ratings:
35%
Hold
33%
Sell
32%
This analysis is based on the reviews of 31 experts in the last 7 days
Lupin Fundamentals
Lupin Financial Ratios
Operating profit margin24.2% | Net profit margin15.79% |
ROE12% | ROA9.77% |
ROCE14.33% |
Learn more
Lupin Share Price history
Day | Open | Close | Change % |
---|---|---|---|
Fri, Nov 1 2024 | ₹2,204.40 | ₹2,197.70 | |
Thu, Oct 31 2024 | ₹2,169.45 | ₹2,186.95 | |
Wed, Oct 30 2024 | ₹2,195.50 | ₹2,158.25 | -2.17% |
Tue, Oct 29 2024 | ₹2,214.65 | ₹2,206.15 | |
Mon, Oct 28 2024 | ₹2,157.05 | ₹2,204.70 | |
Fri, Oct 25 2024 | ₹2,137.80 | ₹2,156.70 | |
Thu, Oct 24 2024 | ₹2,070.00 | ₹2,131.55 | |
Wed, Oct 23 2024 | ₹2,120.40 | ₹2,074.55 | -2.70% |
Events
Corporate actions
Dividend • ₹8/share
Ex date 16 Jul 2024
Dividend • ₹4/share
Ex date 14 Jul 2023
Dividend • ₹4/share
Ex date 14 Jul 2022
Learn more